放射增敏剂
前药
癌症治疗
癌症治疗
癌症
化学
药理学
医学
放射治疗
内科学
标识
DOI:10.2174/187152011796817664
摘要
At present cancer treatment is still a confusing problem. Great progress has been made in anti-tumor agents since a series of small molecules are approved by FDA as anti-tumor drugs. Nitroimidazoles is a kind of radiosensitizer with multiple bioactivities used in cancer treatment since 1950s. In this review, we focus on the development of nitroimidazoles as radiosensitizer, bio-reductive prodrug and other types of anti-tumor agents for cancer therapy, and the mechanism of acting as anti-tumor agents. Finally, we also discuss the prospect and developmental trend of nitroimidazoles as anti-tumor agents. Keywords: Anti-tumor, 2-Nitroimidazole, Hypoxic cell radiosensitizer, Bio-reductive prodrug, Abl tyrosine kinase inhibitor, nitroimidazoles, synergistic effect, normoxia, chemotherapy
科研通智能强力驱动
Strongly Powered by AbleSci AI